newsfilter
← Latest News
PR Newswire·

Miravo Healthcare™ Announces Second Quarter 2021 Results

- Q2 2021 Adjusted Total Revenue - $19.9 million -- Q2 2021 Adjusted EBITDA - $7.4 million -- Blexten Canadian Prescriptions Increased 26% Year-Over-Year -- Cambia Canadian Prescriptions Increased 17% Year-Over-Year - Miravo to Host Conference Call/Aud